Advertisement

Digestive Diseases and Sciences

, Volume 62, Issue 10, pp 2908–2914 | Cite as

Clinical Course of Partial Virologic Response with Prolonged Tenofovir Therapy in Nuclos(t)ides-Naïve Patients with Chronic Hepatitis B

  • In Du Jeong
  • Seok Won Jung
  • Bo Ryung Park
  • Byung Uk Lee
  • Jae Ho Park
  • Byung Gyu Kim
  • Sung-Jo Bang
  • Jung Woo Shin
  • Neung Hwa ParkEmail author
Original Article

Abstract

Background/Aims

The clinical course of chronic hepatitis B (CHB) patients with partial virologic response (PVR) during tenofovir disoproxil fumarate (TDF) therapy remains unclear.

Methods

We retrospectively investigated the long-term clinical outcomes of TDF treatment in nucleos(t)ides-naïve CHB patients, particularly in those with PVR.

Results

A total of 391 patients treated with TDF therapy for more than 12 months were included. Virologic response (VR) was achieved in 341 patients (87.2%). PVR was evident in 127 (45.3%) of the 391 patients. Multivariate logistic regression analysis using selected baseline factors identified absolute HBV DNA levels at baseline (OR 0.496; 95% CI 1.369–1.969) and HBeAg positivity (OR 0.622; 95% CI 1.096–3.167) as factors significantly associated with PVR. During continuous prolonged TDF therapy, 127 (71.8%) of 177 patients with PVR achieved VR. The cumulative rates of VR in patients with PVR at 12, 24, and 36 months were 42.4, 79.7, and 90.2%, respectively. Serum HBV DNA level at week 24 was significantly associated with VR in patients with PVR.

Conclusions

The vast majority of CHB patients with PVR achieved VR through prolonged TDF therapy, although the time to achieve VR was delayed in those with PVR. This suggests that adjustment of TDF therapy in patients with PVR is unnecessary.

Keywords

Tenofovir Partial virologic response Chronic hepatitis B 

Abbreviations

HBV

Hepatitis B virus

NA

Nucleos(t)ide

TDF

Tenofovir disoproxil fumarate

ETV

Entecavir

CHB

Chronic hepatitis B

PVR

Partial virologic response

HBeAg

Hepatitis B e antigen

VR

Virologic response

VBT

Virologic breakthrough

CI

Confidence interval

OR

Odds ratio

ROC

Receiver operating characteristic

AUROC

Area under the ROC curve

HBsAg

Hepatitis B surface antigen

Notes

Acknowledgments

This work was supported by Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2010-0029621).

Compliance with ethical standards

Conflict of interest

The authors declared that they have no conflict of interest.

References

  1. 1.
    Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.CrossRefPubMedGoogle Scholar
  3. 3.
    Levrero M, Testoni B, Zoulim F. HBV cure: Why, how, when? Curr Opin Virol. 2016;18:135–143.CrossRefPubMedGoogle Scholar
  4. 4.
    Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection—EASL special conference. J Hepatol. 2015;63:1238–1253.CrossRefPubMedGoogle Scholar
  5. 5.
    Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.CrossRefPubMedGoogle Scholar
  6. 6.
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.CrossRefPubMedGoogle Scholar
  7. 7.
    Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457–1464.CrossRefPubMedGoogle Scholar
  8. 8.
    Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.CrossRefPubMedGoogle Scholar
  9. 9.
    Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001;34:785–791.CrossRefPubMedGoogle Scholar
  10. 10.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751.CrossRefPubMedGoogle Scholar
  11. 11.
    Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495.CrossRefPubMedGoogle Scholar
  12. 12.
    EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.CrossRefGoogle Scholar
  13. 13.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.CrossRefPubMedGoogle Scholar
  14. 14.
    Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology. 2011;54:443–451.CrossRefPubMedGoogle Scholar
  15. 15.
    Ko SY, Choe WH, Kwon SY, et al. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy. Scand J Gastroenterol. 2012;47:1362–1367.CrossRefPubMedGoogle Scholar
  16. 16.
    Bang SJ, Kim BG, Shin JW, et al. Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B. Dig Liver Dis. 2013;45:600–605.CrossRefPubMedGoogle Scholar
  17. 17.
    Choi HN, Song JE, Lee HC, Jo HH, Lee CH, Kim BS. Efficacy of prolonged entecavir monotherapy in treatment-naive chronic hepatitis B patients exhibiting a partial virologic response to entecavir. Clin Mol Hepatol. 2015;21:24–31.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Korean Association for the Study of the L. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2016;22:18–75.CrossRefGoogle Scholar
  19. 19.
    Ha NB, Ha NB, Garcia RT, et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci. 2011;56:2423–2431.CrossRefPubMedGoogle Scholar
  20. 20.
    Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology. 2011;53:1854–1863.CrossRefPubMedGoogle Scholar
  21. 21.
    Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91–100.CrossRefPubMedGoogle Scholar
  22. 22.
    Kamezaki H, Kanda T, Wu S, et al. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. Scand J Gastroenterol. 2011;46:1111–1117.CrossRefPubMedGoogle Scholar
  23. 23.
    Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol. 2011;54:12–18.CrossRefPubMedGoogle Scholar
  24. 24.
    Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106:1264–1271.CrossRefPubMedGoogle Scholar
  25. 25.
    Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012;57:508–514.CrossRefPubMedGoogle Scholar
  26. 26.
    Shin JW, Jung SW, Park BR, et al. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. J Viral Hepat. 2012;19:724–731.CrossRefPubMedGoogle Scholar
  27. 27.
    European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of Internal Medicine, Ulsan University HospitalUniversity of Ulsan College of MedicineUlsanRepublic of Korea
  2. 2.Biomedical Research Center, Ulsan University HospitalUniversity of Ulsan College of MedicineUlsanRepublic of Korea

Personalised recommendations